Novavax Q3 revenue $85M, net loss $121M; FDA lifts clinical hold on combo vaccine

NOVAVAX INC

2024-Q3 EPS reported -$0.71 revenue$593,851,000

Total revenue $85M (down from $187M YoY); net loss $121M vs $131M; cash $924M as of Sept 30.
FDA removed clinical hold on COVID-19-influenza combination and stand-alone influenza IND candidates.
Full-year 2024 revenue guidance cut to $650-700M from $700-800M; product sales now $175-225M.
Combined R&D/SG&A spend on track; targeting ~$500M in 2025 and ~$350M in 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.